Clinical Trial Update: A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing a trivalent Sabin-strain inactivated poliovirus vaccine to conventional Salk IPV in healthy infants at 6, 10, and 14 weeks, assessing …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Poliomyelitis

Drugs mentioned

• Conventional Salk IPV
• Trivalent Sabin-strain IPV

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Healthy | Phase 2 | Status: COMPLETED